<?xml version="1.0" encoding="UTF-8"?>
<annotations textSource="phac-aspc-gc-ca_20160825T001220.txt">
    <annotation>
        <mention id="EHOST_Instance_3402" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="7614" end="7721" />
        <spannedText>DTaP-IPV or Tdap-IPV vaccine should be used as the booster dose for children at 4 to 6 years of age</spannedText>
        <creationDate>Tue Apr 03 08:53:20 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3402">
        <mentionClass id="claim">DTaP-IPV or Tdap-IPV vaccine should be used as the booster dose for children at 4 to 6 years of age</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3403" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="7730" end="8076" />
        <spannedText>Children 7 years of age and older should receive the adolescent/adult formulation of diphtheria-tetanus-pertussis-containing vaccine, with or without polio, (Tdap or Tdap-IPV) as it contains less diphtheria toxoid than preparations given to younger children and is less likely to cause reactions in older children</spannedText>
        <creationDate>Tue Apr 03 08:53:50 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3403">
        <mentionClass id="claim">Children 7 years of age and older should receive the adolescent/adult formulation of diphtheria-tetanus-pertussis-containing vaccine, with or without polio, (Tdap or Tdap-IPV) as it contains less diphtheria toxoid than preparations given to younger children and is less likely to cause reactions in older children</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3404" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="8078" end="8268" />
        <spannedText>Tdap vaccine should be administered to adolescents at 14 to16 years of age as the first 10-year booster dose; Tdap-IPV vaccine should be used if IPV vaccine is also indicated</spannedText>
        <creationDate>Tue Apr 03 08:53:53 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3404">
        <mentionClass id="claim">Tdap vaccine should be administered to adolescents at 14 to16 years of age as the first 10-year booster dose; Tdap-IPV vaccine should be used if IPV vaccine is also indicated</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3405" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="8271" end="8484" />
        <spannedText>Adults who have not previously received a primary series (at least 3 doses) of tetanus toxoid-containing vaccine should receive one dose of Tdap-IPV vaccine followed by two doses of Td-IPV, vaccine</spannedText>
        <creationDate>Tue Apr 03 08:54:04 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3405">
        <mentionClass id="claim">Adults who have not previously received a primary series (at least 3 doses) of tetanus toxoid-containing vaccine should receive one dose of Tdap-IPV vaccine followed by two doses of Td-IPV, vaccine</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3406" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="9075" end="9281" />
        <spannedText>Children and adults lacking adequate documentation of immunization should be considered unimmunized and started on an immunization schedule appropriate for their age and risk factors</spannedText>
        <creationDate>Tue Apr 03 08:54:31 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3406">
        <mentionClass id="claim">Children and adults lacking adequate documentation of immunization should be considered unimmunized and started on an immunization schedule appropriate for their age and risk factors</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3407" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="10028" end="10228" />
        <spannedText>Premature infants in stable clinical condition should be immunized with a tetanus toxoid-containing preparation at the same chronological age and according to the same schedule as full-term infants</spannedText>
        <creationDate>Tue Apr 03 08:55:01 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3407">
        <mentionClass id="claim">Premature infants in stable clinical condition should be immunized with a tetanus toxoid-containing preparation at the same chronological age and according to the same schedule as full-term infants</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3408" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="10383" end="10516" />
        <spannedText>Hospitalized premature infants should have continuous cardiac and respiratory monitoring for 48 hours after their first immunization</spannedText>
        <creationDate>Tue Apr 03 08:55:09 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3408">
        <mentionClass id="claim">Hospitalized premature infants should have continuous cardiac and respiratory monitoring for 48 hours after their first immunization</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3409" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="11775" end="11950" />
        <spannedText>People with neurological disorders with onset preceding immunization should receive all routinely recommended immunizations, including tetanus toxoid-containing preparations</spannedText>
        <creationDate>Tue Apr 03 08:55:35 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3409">
        <mentionClass id="claim">People with neurological disorders with onset preceding immunization should receive all routinely recommended immunizations, including tetanus toxoid-containing preparations</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3410" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="12342" end="12488" />
        <spannedText>Unimmunized or incompletely immunized travellers should receive diphtheria-tetanus-pertussis-polio-Hib-containing vaccine as appropriate for age</spannedText>
        <creationDate>Tue Apr 03 08:55:58 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3410">
        <mentionClass id="claim">Unimmunized or incompletely immunized travellers should receive diphtheria-tetanus-pertussis-polio-Hib-containing vaccine as appropriate for age</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3411" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="12731" end="12891" />
        <spannedText>Health care providers who see people newly arrived in Canada should review the immunization status and update immunization for these individuals</spannedText>
        <creationDate>Tue Apr 03 08:56:07 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3411">
        <mentionClass id="claim">Health care providers who see people newly arrived in Canada should review the immunization status and update immunization for these individuals</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3412" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="12986" end="13124" />
        <spannedText>All health care workers should be immune to tetanus and receive a booster dose of Td vaccine every 10 years as recommended for all adults</spannedText>
        <creationDate>Tue Apr 03 08:56:13 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3412">
        <mentionClass id="claim">All health care workers should be immune to tetanus and receive a booster dose of Td vaccine every 10 years as recommended for all adults</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3413" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="13126" end="13395" />
        <spannedText>All health care and child care workers, regardless of age, should receive a single dose of Tdap vaccine for pertussis protection if they have not been immunised previously with this vaccine in adulthood, even if they are not due for a tetanus and diphtheria booster</spannedText>
        <creationDate>Tue Apr 03 08:56:19 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3413">
        <mentionClass id="claim">All health care and child care workers, regardless of age, should receive a single dose of Tdap vaccine for pertussis protection if they have not been immunised previously with this vaccine in adulthood, even if they are not due for a tetanus and diphtheria booster</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3414" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="14312" end="14674" />
        <spannedText>Post-exposure prophylaxis of individuals who are unimmunized or incompletely immunized (unknown or fewer than 3 doses) and who sustain more than a minor, clean wound, should consist of both TIg and tetanus toxoid-containing vaccine (as appropriate for age and immunization history), given at different injection sites and using separate needles and syringes</spannedText>
        <creationDate>Tue Apr 03 08:57:11 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3414">
        <mentionClass id="claim">Post-exposure prophylaxis of individuals who are unimmunized or incompletely immunized (unknown or fewer than 3 doses) and who sustain more than a minor, clean wound, should consist of both TIg and tetanus toxoid-containing vaccine (as appropriate for age and immunization history), given at different injection sites and using separate needles and syringes</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3415" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="14813" end="14900" />
        <spannedText>The vaccine series should be completed subsequently unless there is a contraindication</spannedText>
        <creationDate>Tue Apr 03 08:57:26 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3415">
        <mentionClass id="claim">The vaccine series should be completed subsequently unless there is a contraindication</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3416" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="15338" end="15658" />
        <spannedText>People who have a tetanus-prone injury and have experienced a severe injection site reaction following a tetanus toxoid-containing vaccine usually have very high serum antitoxin levels and should not receive routine or emergency booster doses of tetanus toxoid-containing vaccine for 10 years following the last dose</spannedText>
        <creationDate>Tue Apr 03 08:57:48 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3416">
        <mentionClass id="claim">People who have a tetanus-prone injury and have experienced a severe injection site reaction following a tetanus toxoid-containing vaccine usually have very high serum antitoxin levels and should not receive routine or emergency booster doses of tetanus toxoid-containing vaccine for 10 years following the last dose</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3417" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="16047" end="16254" />
        <spannedText>Individuals with humoral immune deficiency who have wounds that are not minor and clean should receive both TIg and tetanus toxoid-containing vaccine, regardless of the time elapsed since the last booster</spannedText>
        <creationDate>Tue Apr 03 08:58:04 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3417">
        <mentionClass id="claim">Individuals with humoral immune deficiency who have wounds that are not minor and clean should receive both TIg and tetanus toxoid-containing vaccine, regardless of the time elapsed since the last booster</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3418" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="16339" end="16501" />
        <spannedText>Persons who have recovered from tetanus disease should receive tetanus toxoid-containing vaccine as recommended for people who not had the disease</spannedText>
        <creationDate>Tue Apr 03 08:58:13 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3418">
        <mentionClass id="claim">Persons who have recovered from tetanus disease should receive tetanus toxoid-containing vaccine as recommended for people who not had the disease</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3419" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="17401" end="17546" />
        <spannedText>When used in the treatment of tetanus, TIg should be administered intramuscularly in an effort to neutralize tetanus toxin in body fluids</spannedText>
        <creationDate>Tue Apr 03 08:59:32 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3419">
        <mentionClass id="claim">When used in the treatment of tetanus, TIg should be administered intramuscularly in an effort to neutralize tetanus toxin in body fluids</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3420" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="17810" end="17927" />
        <spannedText>The gluteal muscle should not be used as an injection site because of the risk of injury to the sciatic nerve</spannedText>
        <creationDate>Tue Apr 03 09:00:14 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3420">
        <mentionClass id="claim">The gluteal muscle should not be used as an injection site because of the risk of injury to the sciatic nerve</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3421" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="18630" end="18758" />
        <spannedText>DTaP-IPV-Hib vaccine should be given at 2, 4, 6 and 12 to 23 months of age (generally given at 18 months of age)</spannedText>
        <creationDate>Tue Apr 03 09:00:35 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3421">
        <mentionClass id="claim">DTaP-IPV-Hib vaccine should be given at 2, 4, 6 and 12 to 23 months of age (generally given at 18 months of age)</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3422" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="19935" end="20205" />
        <spannedText>Children less than 7 years of age not immunized in infancy: should receive three doses of DTaP-IPV (with or without Hib) vaccine with an interval of 8 weeks between doses, followed by a dose of DTaP-IPV vaccine 6 to 12 months after the third dose</spannedText>
        <creationDate>Tue Apr 03 09:01:05 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3422">
        <mentionClass id="claim">Children less than 7 years of age not immunized in infancy: should receive three doses of DTaP-IPV (with or without Hib) vaccine with an interval of 8 weeks between doses, followed by a dose of DTaP-IPV vaccine 6 to 12 months after the third dose</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3423" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="20206" end="20337" />
        <spannedText>A booster dose of either DTaP-IPV or Tdap-IPV vaccine should be administered at 4 to 6 years of age (school entry)</spannedText>
        <creationDate>Tue Apr 03 09:01:11 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3423">
        <mentionClass id="claim">A booster dose of either DTaP-IPV or Tdap-IPV vaccine should be administered at 4 to 6 years of age (school entry)</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3424" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="20912" end="21260" />
        <spannedText>Children who received a primary series) of tetanus toxoid-containing vaccine and a booster dose 6-12 months later as outlined above should receive a booster dose of either DTaP-IPV or Tdap-IPV vaccine at 4 to 6 years of age (school entry); and, 10 years later, a booster dose of Tdap vaccine at 14 to 16 years of age</spannedText>
        <creationDate>Tue Apr 03 09:02:17 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3424">
        <mentionClass id="claim">Children who received a primary series) of tetanus toxoid-containing vaccine and a booster dose 6-12 months later as outlined above should receive a booster dose of either DTaP-IPV or Tdap-IPV vaccine at 4 to 6 years of age (school entry); and, 10 years later, a booster dose of Tdap vaccine at 14 to 16 years of age</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3425" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="21761" end="21851" />
        <spannedText>A booster dose of Tdap vaccine should be administered 10 years after the last dose</spannedText>
        <creationDate>Tue Apr 03 09:02:32 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3425">
        <mentionClass id="claim">A booster dose of Tdap vaccine should be administered 10 years after the last dose</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3426" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="21889" end="22093" />
        <spannedText>Adults who have not previously received a primary series (at least 3 doses) of tetanus toxoid-containing vaccine should receive one dose of Tdap-IPV vaccine and two doses of Td-IPV vaccine</spannedText>
        <creationDate>Tue Apr 03 09:02:39 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3426">
        <mentionClass id="claim">Adults who have not previously received a primary series (at least 3 doses) of tetanus toxoid-containing vaccine should receive one dose of Tdap-IPV vaccine and two doses of Td-IPV vaccine</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3427" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="22103" end="22213" />
        <spannedText>The dose of Tdap-IPV vaccine should be given first, followed 8 weeks later by a dose of Td-IPV vaccine</spannedText>
        <creationDate>Tue Apr 03 09:02:46 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3427">
        <mentionClass id="claim">The dose of Tdap-IPV vaccine should be given first, followed 8 weeks later by a dose of Td-IPV vaccine</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3428" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="22215" end="22330" />
        <spannedText>The second dose of Td-IPV vaccine should be given 6 to 12 months after the previous dose of Td-IPV vaccine</spannedText>
        <creationDate>Tue Apr 03 09:02:50 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3428">
        <mentionClass id="claim">The second dose of Td-IPV vaccine should be given 6 to 12 months after the previous dose of Td-IPV vaccine</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3429" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="22332" end="22444" />
        <spannedText>The preschool booster dose of either DTaP-IPV or Tdap-IPV vaccine should be administered at 4 to 6 years of age</spannedText>
        <creationDate>Tue Apr 03 09:02:55 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3429">
        <mentionClass id="claim">The preschool booster dose of either DTaP-IPV or Tdap-IPV vaccine should be administered at 4 to 6 years of age</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3430" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="22446" end="22540" />
        <spannedText>Adolescents should routinely receive a booster dose of Tdap vaccine at 14 to 16 years of age</spannedText>
        <creationDate>Tue Apr 03 09:02:58 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3430">
        <mentionClass id="claim">Adolescents should routinely receive a booster dose of Tdap vaccine at 14 to 16 years of age</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3431" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="22773" end="23045" />
        <spannedText>Adults who have not received an adult dose of pertussis-containing vaccine should receive one dose of Tdap vaccine, which can be administered regardless of the interval since the last dose of tetanus and diphtheria toxoid-containing vaccine</spannedText>
        <creationDate>Tue Apr 03 09:03:09 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3431">
        <mentionClass id="claim">Adults who have not received an adult dose of pertussis-containing vaccine should receive one dose of Tdap vaccine, which can be administered regardless of the interval since the last dose of tetanus and diphtheria toxoid-containing vaccine</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3432" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="23172" end="23284" />
        <spannedText>Tetanus toxoid-containing preparations should be stored in a refrigerator at +2°C to +8°C and must not be frozen</spannedText>
        <creationDate>Tue Apr 03 09:03:17 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3432">
        <mentionClass id="claim">Tetanus toxoid-containing preparations should be stored in a refrigerator at +2°C to +8°C and must not be frozen</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3433" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="27246" end="27449" />
        <spannedText>Persons experiencing severe injection site reactions usually have very high serum antitoxin concentrations and should not receive further routine doses of Td vaccine for at least 10 years</spannedText>
        <creationDate>Tue Apr 03 09:05:04 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3433">
        <mentionClass id="claim">Persons experiencing severe injection site reactions usually have very high serum antitoxin concentrations and should not receive further routine doses of Td vaccine for at least 10 years</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3434" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="29650" end="29758" />
        <spannedText>Administration of tetanus toxoid-containing vaccine should be postponed in persons with severe acute illness</spannedText>
        <creationDate>Tue Apr 03 09:06:17 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3434">
        <mentionClass id="claim">Administration of tetanus toxoid-containing vaccine should be postponed in persons with severe acute illness</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3435" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="30426" end="30605" />
        <spannedText>People who experience a severe injection site reaction following a dose of tetanus toxoid-containing vaccine should not be given another dose for at least 10 years</spannedText>
        <creationDate>Tue Apr 03 09:06:33 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3435">
        <mentionClass id="claim">People who experience a severe injection site reaction following a dose of tetanus toxoid-containing vaccine should not be given another dose for at least 10 years</mentionClass>
    </classMention>
    <annotation>
        <mention id="EHOST_Instance_3436" />
        <annotator id="eHOST_2010">Benedetta</annotator>
        <span start="30741" end="30917" />
        <spannedText>The primary series of three doses tetanus toxoid-containing vaccine should be completed with an appropriate vaccine from the same manufacturer whenever possible</spannedText>
        <creationDate>Tue Apr 03 09:06:39 MDT 2018</creationDate>
    </annotation>
    <classMention id="EHOST_Instance_3436">
        <mentionClass id="claim">The primary series of three doses tetanus toxoid-containing vaccine should be completed with an appropriate vaccine from the same manufacturer whenever possible</mentionClass>
    </classMention>
    <eHOST_Adjudication_Status version="1.0">
        <Adjudication_Selected_Annotators version="1.0" />
        <Adjudication_Selected_Classes version="1.0" />
        <Adjudication_Others>
            <CHECK_OVERLAPPED_SPANS>false</CHECK_OVERLAPPED_SPANS>
            <CHECK_ATTRIBUTES>false</CHECK_ATTRIBUTES>
            <CHECK_RELATIONSHIP>false</CHECK_RELATIONSHIP>
            <CHECK_CLASS>false</CHECK_CLASS>
            <CHECK_COMMENT>false</CHECK_COMMENT>
        </Adjudication_Others>
    </eHOST_Adjudication_Status>
</annotations>

